{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-035542","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2026-05-15T20:03:00+00:00","discovered_at":"2026-05-15T20:07:00.428292+00:00","generated_at":"2026-05-15T20:09:05.088476+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"C4 Therapeutics CFO Adams assumes principal accounting officer; Mossler departs","bullets":["Mark Mossler to cease as Chief Accounting Officer effective May 15, 2026; departure not due to any disagreement.","CFO Kendra R. Adams designated as principal accounting officer, effective May 15, 2026.","Adams receives no additional compensation for assuming the additional role."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-035542","json":"https://secwatch.observer/filing/0001628280-26-035542.json","markdown":"https://secwatch.observer/filing/0001628280-26-035542.md","text":"https://secwatch.observer/filing/0001628280-26-035542.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/0001628280-26-035542-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/cccc-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T20:09:05.088476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c3dbdb97e","claim":"Kendra R. Adams changed role as Chief Financial Officer, Head of Corporate Affairs and Treasurer at C4 Therapeutics, Inc..","evidence_excerpt":"Kendra R. Adams, the Company's Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the Company's principal accounting officer, effective May 15, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/0001628280-26-035542-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"designated as principal accounting officer"},{"label":"Role","value":"Chief Financial Officer, Head of Corporate Affairs and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"ac48cd1aa0","claim":"Mark Mossler departed as Chief Accounting Officer at C4 Therapeutics, Inc..","evidence_excerpt":"Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/0001628280-26-035542-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will no longer serve"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}